Abstract
Vorapaxar is a first-in-class platelet protease activated receptor (PAR)-1 receptor antagonist available for secondary prevention in patients with stable atherosclerosis without a history of stroke or TIA. In light of increased risk both of thrombotic events and bleeding in elderly patients, the
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
